New Once-Daily pill aims to tame ADHD symptoms in korean youth
NCT ID NCT07678827
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 3 trial tests whether viloxazine extended-release capsules, taken once daily, can safely reduce ADHD symptoms in Korean children and adolescents aged 6 to 17. Participants receive either the drug or a placebo for 8 weeks, with doses adjusted based on response. The study measures changes in ADHD rating scores to see if the medication works better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
viloxazine extended-release capsules
What this could lead to
If successful, this could provide a new once-daily medication option for managing ADHD symptoms in Korean children and adolescents.
What could go wrong
This is a bridging trial with a relatively small sample size (156 participants) and short duration (8 weeks), so results may not generalize to broader populations or long-term use. Side effects are possible, as with any medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••